Balyasny Asset Management
BSX icon

Balyasny Asset Management’s Boston Scientific BSX Stock Holding History

Balyasny Asset Management’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$85.1M Sell
1,356,133
-1,125,616
-45% -$90M 0.11% 194
2025
Q4 		$237M Buy
2,481,749
+927,848
+60% +$91M 0.3% 46
2025
Q3 		$152M Buy
1,553,901
+48,988
+3% +$5.07M 0.19% 97
2025
Q2 		$162M Sell
1,504,913
-333,266
-18% -$33.7M 0.24% 73
2025
Q1 		$185M Buy
1,838,179
+71,571
+4% +$7.21M 0.31% 50
2024
Q4 		$158M Sell
1,766,608
-1,688,996
-49% -$149M 0.24% 83
2024
Q3 		$290M Buy
3,455,604
+539,531
+19% +$42.5M 0.47% 23
2024
Q2 		$225M Buy
2,916,073
+1,322,739
+83% +$96.8M 0.39% 29
2024
Q1 		$109M Buy
1,593,334
+260,778
+20% +$16.8M 0.19% 101
2023
Q4 		$77M Buy
1,332,556
+1,324,980
+17,489% +$70.7M 0.14% 170
2023
Q3 		$400K Sell
7,576
-11,336
-60% -$595K ﹤0.01% 1819
2023
Q2 		$1.02M Sell
18,912
-575,106
-97% -$30M ﹤0.01% 1612
2023
Q1 		$29.7M Buy
+594,018
New +$28M 0.07% 383
2022
Q4 		– Sell
-2,347,335
Closed -$90.9M – 2801
2022
Q3 		$90.9M Buy
2,347,335
+1,163,565
+98% +$46.7M 0.28% 69
2022
Q2 		$44.1M Buy
1,183,770
+707,487
+149% +$28.8M 0.14% 179
2022
Q1 		$21.1M Buy
+476,283
New +$20.6M 0.07% 397
2021
Q4 		– Sell
-2,155,328
Closed -$93.5M – 2259
2021
Q3 		$93.5M Buy
2,155,328
+423,352
+24% +$18.7M 0.39% 32
2021
Q2 		$74.1M Buy
+1,731,976
New +$72.9M 0.35% 48
2020
Q3 		– Sell
-148,178
Closed -$5.71M – 1304
2020
Q2 		$5.2M Sell
148,178
-2,031,758
-93% -$73.2M 0.05% 508
2020
Q1 		$71.1M Buy
2,179,936
+1,853,465
+568% +$72.4M 0.84% 10
2019
Q4 		$14.8M Buy
+326,471
New +$13.7M 0.09% 328
2019
Q2 		– Sell
-616,675
Closed -$23.7M – 1483
2019
Q1 		$23.7M Buy
+616,675
New +$23.6M 0.16% 193
2018
Q4 		– Sell
-468,618
Closed -$18M – 1419
2018
Q3 		$18M Sell
468,618
-327,892
-41% -$11.5M 0.08% 330
2018
Q2 		$26M Buy
796,510
+668,139
+520% +$20.2M 0.12% 241
2018
Q1 		$3.51M Sell
128,371
-808,738
-86% -$22M 0.01% 816
2017
Q4 		$23.2M Sell
937,109
-44,815
-5% -$1.24M 0.07% 357
2017
Q3 		$28.6M Sell
981,924
-917,642
-48% -$25.3M 0.11% 242
2017
Q2 		$52.7M Buy
1,899,566
+1,838,876
+3,030% +$48.8M 0.22% 111
2017
Q1 		$1.51M Sell
60,690
-14,989
-20% -$364K 0.01% 989
2016
Q4 		$1.64M Sell
75,679
-2,369,109
-97% -$51.7M 0.01% 917
2016
Q3 		$58.2M Sell
2,444,788
-228,589
-9% -$5.45M 0.34% 84
2016
Q2 		$62.5M Buy
+2,673,377
New +$57.8M 0.4% 50
2016
Q1 		– Sell
-811,023
Closed -$15M – 1285
2015
Q4 		$15M Buy
811,023
+318,423
+65% +$5.71M 0.1% 261
2015
Q3 		$8.08M Buy
+492,600
New +$8.42M 0.06% 403
2013
Q4 		– Sell
-1,130,172
Closed -$13.3M – 500
2013
Q3 		$13.3M Buy
1,130,172
+126,292
+13% +$1.37M 0.18% 149
2013
Q2 		$9.31M Buy
+1,003,880
New +$8.52M 0.16% 160

Other funds holding BSX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Balyasny Asset Management's BSX Position: Q1 2026 in Review

Balyasny Asset Management reduced its Boston Scientific (BSX) stake by 45% in Q1 2026, selling an estimated $90M and leaving 1,356,133 shares worth $85.1M. The position accounts for 0.11% of the portfolio, ranked #194.

Balyasny Asset Management first reported a position in BSX in Q2 2013 and has held it in 36 quarters since. The position peaked at $290M in Q3 2024. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Balyasny Asset Management held 1,356,133 shares of Boston Scientific worth $85.1M as of Q1 2026.
  • Balyasny Asset Management sold 1,125,616 Boston Scientific shares in Q1 2026, an estimated $90M.
  • Boston Scientific made up 0.11% of Balyasny Asset Management's portfolio in Q1 2026, its #194 holding.
  • Balyasny Asset Management first reported a position in Boston Scientific in Q2 2013 and has held it in 36 quarters since.
  • Balyasny Asset Management's Boston Scientific position peaked at $290M in Q3 2024.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.